IM8N Stock Chart & Stats
€107.74
-€0.11(-0.12%)
At close: 4:00 PM EDT
€107.74
-€0.11(-0.12%)
Day’s Range― - ―
52-Week Range€81.86 - €185.00
Previous CloseN/A
Volume4.00
Average Volume (3M)4.00
Market Cap
€20.17B
Enterprise Value€22.76B
Total Cash (Recent Filing)€1.16B
Total Debt (Recent Filing)€579.88M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Oct 29, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding218,381,500
10 Day Avg. Volume9
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-1.80
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€176.66Price Target Upside63.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)-1.42
Revenue Forecast (FY)€1.60B
Bulls Say, Bears Say
Bulls Say
BRINSUPRI Commercial MomentumRapid patient adoption, expanding prescriber depth, and raised revenue guidance indicate strong early commercial execution. If these trends persist, BRINSUPRI can become a substantial recurring revenue base and improve Insmed’s operating leverage as launch investments mature.
Strong Revenue Growth And Gross MarginAccelerating revenue growth combined with high and improving gross margin gives Insmed meaningful gross-profit generation from incremental sales. This supports reinvestment in launches and clinical programs while creating a foundation for future operating leverage, despite current losses.
Pipeline And Clinical AdvancementPositive longer-term TPIP data and continued advancement of additional programs broaden Insmed’s future product opportunity beyond ARIKAYCE. A diversified pipeline can support durable growth and reduce reliance on one commercial therapy if clinical and regulatory execution continues.
Bears Say
Heavy Losses And Cash BurnInsmed remains materially unprofitable and consumes substantial cash while funding launches and development programs. Continued losses reduce financial flexibility and make the expected transition to cash-flow positivity dependent on successful commercialization, disciplined spending, and timely execution.
Rising Investment And Milestone OutflowsHigher commercial and clinical spending is necessary to pursue growth but intensifies near-term cash demands before new products fully scale. Milestone obligations add committed outflows, increasing execution pressure and leaving less room for setbacks during the path toward projected 2027 cash-flow positivity.
European Revenue HeadwindsLess favorable European reimbursement economics can reduce the size and profitability of Insmed’s international opportunity. A diminished regional contribution would increase dependence on U.S. launches and other markets, making long-term growth more concentrated and sensitive to execution there.
Insmed News
IM8N FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was €81.86 and its highest was €185.00 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is €20.17B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Oct 29, 2026 which is in 22 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Aug 06, 2026. The company reported -€0.053 earnings per share for the quarter, beating the consensus estimate of -€0.598 by €0.545.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.35.
How many shares outstanding does Insmed have?
Insmed has 218,381,500 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -€0.053 in its last earnings report, beating expectations of -€0.598. Following the earnings report the stock price went up 32.334%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in DE:IM8N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€176.66 (63.97% Upside)
€176.66 (63.97% Upside)
Blogger Sentiment
Bullish
DE:IM8N Sentiment 73%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €31.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
IM8N Company Deck
IM8N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and materially improved financial and clinical momentum — highlighted by BRINSUPRI’s historic launch ($309.2M Q2, raised FY guidance to $1.25B–$1.4B, peak >$7B), solid ARIKAYCE performance ($116.3M, +8% YoY) and compelling TPIP clinical data with upgraded peak potential (> $6B). Management emphasized a healthy cash position (~$1.2B) and a clear path to cash-flow positivity in 2027. Offsetting risks include higher near-term operating spend (R&D and SG&A +38% YoY), European reimbursement headwinds, milestone payments (~$50M H2 2026), and reliance on optimistic assumptions (diagnosis expansion, regulatory success, pricing). Overall, the positive commercial results, clinical readouts and funding runway substantially outweigh the noted operational and market uncertainties.View all DE:IM8N earnings summariesIM8N Stock 12 Month Forecast
Average Price Target
€176.66
▲(63.97% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
United Therapeutics
―
Ultragenyx Pharmaceutical
―
Avalyn Pharma Inc
―